Lan Su, COO of Lakeside Holding, Shares His Vision and Strategies for Charting New Horizons
Biotech Health X recently had the opportunity to sit down with Lan Su, the newly appointed Chief Operating…
Pioneering Cell & Exosome Therapies for Rare Diseases | Capricor Therapeutics Interview with Dr. Linda Marbán and AJ Bergmann
Join us on BioTech Health X as we sit down with Dr. Linda Marbán, CEO, and AJ Bergmann,…
The Future of Cell & Gene Therapy Logistics with Cryoport | Interview with CEO Mark Sawicki
In an exclusive interview with BioTech Health X host Allison Goodlove, Cryoport (NASDAQ: CYRX) President & CEO Mark…
Geert Kersten on CEL-SCI’s Multikine and the Future of Immunotherapy – Exclusive Interview
In this exclusive interview, host Allison Godlove sits down with CEL-SCI (NYSEAMERICAN: CVM) CEO Geert Kersten to delve…
SyneuRx CEO Dr. Emil Tsai Exclusive Interview with Insights & Projections
Our BioTech Health X CEO Series continues with an exclusive interview with Dr. Emil Tsai of SyneuRx. Today…
BioTech Health X CEO Series: Virios Therapeutics Greg Duncan
BioTech Health X works to deliver the latest coverage and updates in the biotechnology sector. This includes providing…
Ortho Clinical Diagnostics Overview & Q&A Interview
Michael S. Iskra, Executive Vice President of Commercial Excellence and Strategy at Ortho Clinical Diagnostics I’d be happy…
Xontogeny CEO Chris Garabedian Exclusive Interview [September 2021]
As we expand our coverage of the biotechnology sector with the latest biotech news, our team at BioTech…
Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
About Cel-Sci Corporation Cel-Sci Corporation is a publicly traded biotechnology business which develops, manufactures, and markets treatments focused…